An observational study in Allergic Rhinoconjunctivitis, sponsored by Bitop AG. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-05-06.
Sponsored by Bitop AG · Observational
This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops. In addition the effectiveness and safety shall be compared to Azelastine containing nasal Sprays and Eye drops. The patient applied Ectoin® Rhinitis Nasal Spray / Eye drops or takes Azelastine nasals spray and eye drops according to the instructions for use. The observation takes place over a period of 7 days. Response to treatment is recorded at day 7 by the physician and in daily by the patient in a dairy.
1,042 studies on the registry are indexed under Rhinitis, Allergic; 91 are open to participants now.
This study's enrollment of 48 is below the median of 126 across 158 observational studies indexed under Rhinitis, Allergic.
Browse Rhinitis, Allergic studies →Bitop AG is the lead sponsor of 26 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary Care Clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Azelastine nasal spray Azelastine eye drops
Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
Change in primary allergic symptoms symptoms
Change in the primary allergic nasal and ophthalmic symptoms: Degree of nasal breathing impairment, Rhinorrhea, Frequency of sneezing, Nasal itching,Eye itching, Watery eyes, Conjunctivitis score (eye redness)
Time frame: Day1, Day 7
Palatal itching score
Time frame: day 1 and day 7
Efficacy and tolerability assessment by the patients
Patients assess the efficacy and tolerability separately based on a general an Scale from 0 to 8
Time frame: day1 and day 7
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.